Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis (PETE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified December 2008 by African Poverty Related Infection Oriented Research Initiative.
Recruitment status was: Recruiting

Sponsor:

Collaborators:

Radboud University

Kilimanjaro Christian Medical Centre, Tanzania

Information provided by:

African Poverty Related Infection Oriented Research Initiative

ClinicalTrials.gov Identifier:

NCT00474435

First received: May 16, 2007

Last updated: December 16, 2010

Last verified: December 2008

History of Changes

Purpose

In this pilot study the pharmacokinetics and safety of the antiretroviral combination of co-formulated emtricitabine/tenofovir/efavirenz will be studied in HIV-positive patients with pulmonary tuberculosis (TB) who are concomitantly treated with a standard rifampin-containing tuberculostatic regimen. It is expected that this antiretroviral combination causes minimal drug interactions with the rifampin-containing anti-tuberculosis medication.

Condition	Intervention	Phase
Tuberculosis HIV Infections	Drug: Emtricitabine/tenofovir/efavirenz	Phase 2


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Tuberculosis

Drug Information available for: Emtricitabine Tenofovir Efavirenz Tenofovir Disoproxil Fumarate

Genetic and Rare Diseases Information Center resources: Tuberculosis

U.S. FDA Resources

Further study details as provided by African Poverty Related Infection Oriented Research Initiative:

Primary Outcome Measures:

Pharmacokinetic parameters of emtricitabine, tenofovir and efavirenz [ Time Frame: Two 24 hour pharmacokinetic (PK) curves (week 8 and 28) ]
Pharmacokinetic parameters of the tuberculostatic agents [ Time Frame: Pharmacokinetic (PK) samples at 2 hours and 6 hours postdose (week 2 and 8) ]

Secondary Outcome Measures:

Biochemistry and haematology samples for safety [ Time Frame: Samples at screening, baseline, week 2, 4, 6, 8, 12, 16, 24, 28 ]
Questioning about occurrence of adverse events [ Time Frame: At baseline, week 2, 4, 6, 8, 12, 16, 24, 28 ]
CD4 count and HIV-1 RNA [ Time Frame: At screening, week 4, week 16 and week 28 ]
Sputum staining and culture [ Time Frame: At screening, week 4, 8, and 28 ]


Estimated Enrollment:	30
Study Start Date:	November 2008
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Intervention Details:

Co-formulated in one tablet (taken once daily by oral administration):

emtricitabine 200 mg
tenofovir DF 300 mg
efavirenz 600 mg

Detailed Description:

The primary objectives of this pilot study in 30 patients are:

To determine the effect of rifampin-containing tuberculostatic treatment on the pharmacokinetic profile of emtricitabine+tenofovir+efavirenz, when co-formulated in one tablet, in HIV-infected patients with smear-positive pulmonary tuberculosis in Tanzania.
To determine the effect of the emtricitabine+tenofovir+efavirenz regimen on the pharmacokinetics of tuberculostatics in the same population.

The secondary objectives are:

To determine the safety of co-administration of emtricitabine+tenofovir+efavirenz with treatment for smear-positive pulmonary tuberculosis.
To determine the short-term (24 weeks) virological efficacy on HIV of an emtricitabine+tenofovir+efavirenz regimen in patients with smear-positive pulmonary tuberculosis.
To determine the short-term bacteriological efficacy on smear-positive tuberculosis of the co-administration of a standard regimen for tuberculosis and an emtricitabine+tenofovir+efavirenz regimen.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

A smear-positive pulmonary tuberculosis, based on positive smear of at least two sputum samples with Ziehl-Neelsen (ZN) staining.
HIV-infected as documented by positive HIV antibody test.
Subject is at least 18 years of age at the day of the first dosing of study medication.
Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
CD4 cell count > 50 copies/mm3.
Karnofsky score > 40.
Willing and able to regularly attend the Kibung'oto National Tuberculosis Hospital (KNTH) clinic.

Exclusion Criteria:

History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients, which may be employed in the trial.
Previously treated for HIV infection with antiretroviral agents.
Pregnant or breastfeeding.
Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
A history of severe psychiatric disease such as psychosis, schizophrenia, etc.
Inability to understand the nature and extent of the trial and the procedures required.
Abnormal serum transaminases or creatinine, determined as levels being > 5 times upper limit of normal.
Active hepatobiliary or hepatic disease (Non B Chronic Hepatitis B/C co-infection is allowed).
CD4 cell count > 350 cells/mm3.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00474435

Contacts


Contact: Gibson Kibiki, MMed, PhD	+255 754 572767	gkibiki@gmail.com
Contact: Jossy van den Boogaard, MD	+255 787 148431	jossyvandenboogaard@gmail.com

Locations


Tanzania
Kibong'oto National Tuberculosis Hospital	Recruiting
Moshi, Kilimanjaro Region, Tanzania, P.O. Box 12
Contact: Liberate Mleoh, MD 027 2756194 lmleoh@yahoo.com
Principal Investigator: Gibson Kibiki, MMed, PhD
Sub-Investigator: Elton Kisanga, B-Pharm, PhD
Sub-Investigator: Liberate Mleoh, MD
Sub-Investigator: Jossy van den Boogaard, MD
Sub-Investigator: Hadija Semvua, B-Pharm, MPH
Sub-Investigator: Charles Mtabho, MD, MPH

Sponsors and Collaborators

African Poverty Related Infection Oriented Research Initiative

Radboud University

Kilimanjaro Christian Medical Centre, Tanzania

Investigators


Principal Investigator:	Martin Boeree, MD, PhD	University Lungcentre Dekkerswald, Groesbeek / University Medical Centre Nijmegen, the Netherlands
Principal Investigator:	David Burger, PharmD, PhD	University Medical Centre Nijmegen, the Netherlands
Principal Investigator:	Gibson Kibiki, MMed, PhD	Kilimanjaro Christian Medical Centre,Moshi,Tanzania

More Information

Publications:

Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet. 2000 Oct 28;356(9240):1488-9.

Msamanga GI, Fawzi WW. The double burden of HIV infection and tuberculosis in sub-Saharan Africa. N Engl J Med. 1997 Sep 18;337(12):849-51.

Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002 Jan 4;16(1):75-83.

Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327-41. Review.

Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002 May 13;162(9):985-92. Review.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681-90.

Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 Jul;37(7):1426-31.

Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, Foster BC, Cameron DW. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol. 1999 Aug;48(2):168-79.

Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack C, Gandhi N, El Sadr W. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S421-8.

Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):287-91.

Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD; Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004 Mar;48(3):824-31.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001 Jan 5;15(1):71-5.


Responsible Party:	Martin Boeree, University Lungcentre Dekkerswald, Groesbeek, the Netherlands
ClinicalTrials.gov Identifier:	NCT00474435 History of Changes
Other Study ID Numbers:	UMCN-AKF 04.03
Study First Received:	May 16, 2007
Last Updated:	December 16, 2010

Keywords provided by African Poverty Related Infection Oriented Research Initiative:


Tuberculosis HIV Coinfection Pharmacokinetics Emtricitabine	Tenofovir Rifampin Efavirenz Treatment Naive

Additional relevant MeSH terms:


HIV Infections Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Tenofovir	Emtricitabine Efavirenz Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers

HIV Infections
Tuberculosis
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Tenofovir

Emtricitabine
Efavirenz
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers

ClinicalTrials.gov processed this record on September 20, 2017

To Top